Commentary & Deal Flow

Almirall SA EUR250m 144A/Reg S sr notes due 2026 (5y). NC2 (50%,25%,par). Ba3/BB- (stable/stable). Via BNP/JPM (B&D) jt glocos/BBVA/BofA/Caixa/Santander jt books. No reg rights. List lux. NY law.

IPT: mid 2s.

Did investor call at 11am UKT yesterday. Virtual 1x1s yesterday - tomorrow. UOP: along with EUR5m cash on hand, to repay its EUR250m 0.25% cvt notes due 12/14/21. Biz: Almirall is a publicly listed pharmaceutical company that researches, develops, produces and markets a fairly diversified portfolio of in-house developed drugs and in-licensed drugs in therapeutic areas including dermatology, respiratory, gastrointestinal and pain relief. HQ: Barcelona, Spain.